Phase 2 Myasthenia Gravis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with generalized myasthenia gravis (a muscle weakness condition), confirmed by blood tests showing specific antibodies (AChR or MuSK), plus at least one additional test or treatment response supporting the diagnosis.
- Your myasthenia gravis is classified as moderately severe to moderately severe with some breathing or swallowing difficulties (confirm with trial site for exact classification).
- Your condition has not responded well enough to at least two different non-steroid immune-suppressing medications taken at the right doses and for long enough, and your daily life is significantly affected by symptoms.
- If you are taking steroid medications long-term, your dose has been stable for at least one month before the start of the study, and you are willing and able to reduce the dose to a low level before a specific procedure called leukapheresis (a blood cell collection process).
- If you are taking medications to help with muscle weakness (cholinesterase inhibitors), your dose has been stable for at least two weeks before the study begins.
Who may not be able to join:
- Your myasthenia gravis only affects your eyes, causes only mild symptoms, involves severe swallowing or breathing problems, or you are currently in a myasthenia gravis crisis.
- You have previously had a bone marrow, stem cell, or solid organ transplant (such as a kidney or liver transplant).
- You have a significant active infection, a long-term recurring infection, or you have tested positive for hepatitis B or hepatitis C within one month before the blood collection procedure.
- You have another uncontrolled health condition, such as severe asthma or inflammatory bowel disease, that often requires steroid treatment.
- You have a known immune system deficiency condition (such as HIV/AIDS or an inherited immune disorder), or you have tested positive for HIV.
- You have previously been treated with certain advanced therapies, including anti-CD19 treatments, CAR-T cell therapy, or any other gene therapy.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: 1-888-669-6682
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Occurrence, severity, and frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.